{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:09:02Z","timestamp":1762956542443,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40266-021-00843-9","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T01:19:25Z","timestamp":1614647965000},"page":"417-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Risk of Falling and Consequences of Falling in Patients with Atrial Fibrillation Receiving Different Types of Anticoagulant"],"prefix":"10.1007","volume":"38","author":[{"given":"Ivana","family":"Jurin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-2040","authenticated-orcid":false,"given":"Marko","family":"Lucijani\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vedran","family":"Radoni\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomislav","family":"Letilovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Lucijani\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stjepan","family":"Mesarov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Zagorec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irzal","family":"Had\u017eibegovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"issue":"8","key":"843_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837\u201347.","journal-title":"Circulation"},{"issue":"12","key":"843_CR2","doi-asserted-by":"publisher","first-page":"e009522","DOI":"10.1136\/bmjopen-2015-009522","volume":"5","author":"M Torstensson","year":"2015","unstructured":"Torstensson M, Hansen AH, Leth-M\u00f8ller K, J\u00f8rgensen TS, Sahlberg M, Andersson C, et al. Danish register-based study on the association between specific cardiovascular drugs and fragility fractures. BMJ Open. 2015;5(12):e009522.","journal-title":"BMJ Open."},{"doi-asserted-by":"crossref","unstructured":"Summary of the Updated American Geriatrics Society\/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. J Am Geriatr Soc. 2011;59(1):148\u201357.","key":"843_CR3","DOI":"10.1111\/j.1532-5415.2010.03234.x"},{"issue":"4","key":"843_CR4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/ageing\/afv017","volume":"44","author":"S Jansen","year":"2015","unstructured":"Jansen S, Frewen J, Finucane C, de Rooij SE, van der Velde N, Kenny RA. AF is associated with self-reported syncope and falls in a general population cohort. Age Ageing. 2015;44(4):598\u2013603.","journal-title":"Age Ageing"},{"issue":"5","key":"843_CR5","first-page":"436","volume":"29","author":"C-Y Hung","year":"2013","unstructured":"Hung C-Y, Wu T-J, Wang K-Y, Huang J-L, Loh E-W, Chen Y-M, et al. Falls and atrial fibrillation in elderly patients. Acta Cardiologica Sinica. 2013;29(5):436\u201343.","journal-title":"Acta Cardiologica Sinica."},{"issue":"5","key":"843_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3325\/cmj.2020.61.440","volume":"61","author":"I Jurin","year":"2020","unstructured":"Jurin I, Lucijanic M, Sakic Z, Hulak Karlak V, Atic A, Maglicic A, et al. Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry. Croat Med J. 2020;61(5):440\u20139.","journal-title":"Croat Med J."},{"issue":"4","key":"843_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1345\/aph.1K498","volume":"42","author":"CL Garwood","year":"2008","unstructured":"Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother. 2008;42(4):523\u201332.","journal-title":"Ann Pharmacother."},{"issue":"5","key":"843_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","volume":"50","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardio-Thorac Surg. 2016;50(5):e1\u201388.","journal-title":"Eur J Cardio-Thorac Surg"},{"issue":"12","key":"843_CR9","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.amjcard.2019.02.060","volume":"123","author":"AH Malik","year":"2019","unstructured":"Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients > 75 years of age. Am J Cardiol. 2019;123(12):2051\u20137.","journal-title":"Am J Cardiol."},{"issue":"13","key":"843_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/heartjnl-2017-312720","volume":"104","author":"G Savarese","year":"2018","unstructured":"Savarese G, Sartipy U, Friberg L, Dahlstr\u00f6m U, Lund LH. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. Heart. 2018;104(13):1093\u2013100.","journal-title":"Heart"},{"issue":"10","key":"843_CR11","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.amjcard.2017.07.091","volume":"120","author":"TA Durham","year":"2017","unstructured":"Durham TA, Hassmiller Lich K, Viera AJ, Fine JP, Mukherjee J, Weinberger M, et al. Utilization of standard and target-specific oral anticoagulants among adults in the United Kingdom with incident atrial fibrillation. Am J Cardiol. 2017;120(10):1820\u20139.","journal-title":"Am J Cardiol."},{"issue":"4","key":"843_CR12","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.amjcard.2015.11.032","volume":"117","author":"M Bo","year":"2016","unstructured":"Bo M, Sciarrillo I, Li Puma F, Badinella Martini M, Falcone Y, Iacovino M, et al. Effects of oral anticoagulant therapy in medical inpatients \u2265 65 years with atrial fibrillation. Am J Cardiol. 2016;117(4):590\u20135.","journal-title":"Am J Cardiol."},{"issue":"2","key":"843_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372.","journal-title":"Chest"},{"issue":"5","key":"843_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093\u2013100.","journal-title":"Chest"},{"key":"843_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1017\/S0714980800008576","volume":"8","author":"J Morse","year":"1989","unstructured":"Morse J, Morse R, Tylko S. Development of a scale to identify the fall-prone patient. Can J Aging. 1989;8:366\u20137.","journal-title":"Can J Aging."},{"issue":"2","key":"843_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.11613\/BM.2012.018","volume":"22","author":"M Lucijanic","year":"2012","unstructured":"Lucijanic M, Petrovecki M. Analysis of censored data. Biochemia medica. 2012;22(2):151\u20135.","journal-title":"Biochemia medica."},{"issue":"1","key":"843_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3325\/cmj.2016.57.77","volume":"57","author":"M Lucijanic","year":"2016","unstructured":"Lucijanic M. Survival analysis in clinical practice: analyze your own data using an Excel workbook. Croat Med J. 2016;57(1):77\u20139.","journal-title":"Croat Med J."},{"issue":"3","key":"843_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1447-0594.2011.00783.x","volume":"12","author":"T Kojima","year":"2012","unstructured":"Kojima T, Akishita M, Nakamura T, Nomura K, Ogawa S, Iijima K, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012;12(3):425\u201330.","journal-title":"Geriatr Gerontol Int."},{"issue":"2","key":"843_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/1753944712464101","volume":"7","author":"JC LaMori","year":"2013","unstructured":"LaMori JC, Mody SH, Gross HJ, daCosta DM, Patel AA, Schein JR, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53\u201362.","journal-title":"Ther Adv Cardiovasc Dis."},{"issue":"353","key":"843_CR20","doi-asserted-by":"publisher","first-page":"i2868","DOI":"10.1136\/bmj.i2868","volume":"15","author":"J Jaspers Focks","year":"2016","unstructured":"Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;15(353):i2868.","journal-title":"BMJ"},{"issue":"9","key":"843_CR21","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/ijcp.12863","volume":"70","author":"GY Lip","year":"2016","unstructured":"Lip GY, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a \u201creal-world\u201d observational study in the United States. Int J Clin Pract. 2016;70(9):752\u201363.","journal-title":"Int J Clin Pract"},{"issue":"209","key":"843_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijcard.2016.02.005","volume":"15","author":"PA Noseworthy","year":"2016","unstructured":"Noseworthy PA, Yao X, Shah ND, Gersh BJ. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol. 2016;15(209):181\u20133.","journal-title":"Int J Cardiol"},{"issue":"5","key":"843_CR23","first-page":"975","volume":"116","author":"GY Lip","year":"2016","unstructured":"Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116(5):975\u201386.","journal-title":"Thromb Haemost."},{"issue":"2","key":"843_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ahj.2010.11.002","volume":"161","author":"MB Sellers","year":"2011","unstructured":"Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161(2):241\u20136.","journal-title":"Am Heart J"},{"issue":"8","key":"843_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.amjmed.2012.01.033","volume":"125","author":"J Donz\u00e9","year":"2012","unstructured":"Donz\u00e9 J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125(8):773\u20138.","journal-title":"Am J Med."},{"issue":"301","key":"843_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijcard.2019.10.035","volume":"15","author":"M Lucijanic","year":"2020","unstructured":"Lucijanic M, Jurin I, Jurin H, Lucijanic T, Starcevic B, Skelin M, et al. Patients with higher body mass index treated with direct\/novel oral anticoagulants (DOAC\/NOAC) for atrial fibrillation experience worse clinical outcomes. Int J Cardiol. 2020;15(301):90\u20135.","journal-title":"Int J Cardiol"},{"issue":"8","key":"843_CR27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00380-017-0950-2","volume":"32","author":"S Namba","year":"2017","unstructured":"Namba S, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Hashikata T, et al. Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels. 2017;32(8):977\u201382.","journal-title":"Heart Vessels"},{"issue":"2","key":"843_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/jamainternmed.2019.5679","volume":"180","author":"PL Lutsey","year":"2019","unstructured":"Lutsey PL, Norby FL, Ensrud KE, MacLehose RF, Diem SJ, Chen LY, et al. Association of anticoagulant therapy with risk of fracture among patients with atrial fibrillation. JAMA Intern Med. 2019;180(2):245\u201353.","journal-title":"JAMA Intern Med."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00843-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-021-00843-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00843-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T07:17:36Z","timestamp":1620112656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-021-00843-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1007\/s40266-021-00843-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"type":"print","value":"1170-229X"},{"type":"electronic","value":"1179-1969"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"6 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"IJ and TL have received speaker honoraria from Boehringer Ingelheim. IH has received speaker honoraria from Boehringer Ingelheim, Pfizer, and Bayer. Marko Lucijani\u0107, Vedran Radoni\u0107, Jelena Lucijani\u0107, Stjepan Mesarov, and Nikola Zagorec have no conflicts of interest that are directly relevant to the content of this article","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the relevant institutional review boards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable as this was a retrospective study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable as commercial statistical software was used.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"IJ, ML, and IH conceptualized the study and drafted the manuscript. ML performed statistical analysis. All authors participated in data acquisition and interpretation, critical revision of the manuscript, and final approval of the submitted version. All authors agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}